Table 5.

Summary of copper(II) clusters coordinated to O N O ligands with better IC₅₀ values (μM) in different cell lines.

Compound	Metal geometry	Exposure time [h]	Cell lines	IC50 value [μM]	Main feature	Ref.
Cu‐54	Square pyramidal and octahedral	48	HeLa HL‐60 Caco‐2 A‐549	13.50±1.21 13.85±1.39 13.88±1.22 20.01±1.09	Anticancer activity depends on chirality and interactions with DNA	[81]
Cu‐58			A‐549 HCT‐116 HL‐60 K‐562	16.05 30.02 13.17 27.28	Anticancer activity depends on the nuclearity and nature of the metal centre	[84]
Cu‐59	Square pyramidal		HeLa MDA‐MB‐231 A‐549	17.94±1.25 6.20±0.79 29.68±1.47	Anticancer activity depends on chirality and nuclearity	[85]
Cu‐60	Octahedral		HeLa HL‐60 Caco‐2 A‐549	12.67±1.29 11.83±1.43 15.61±1.15 18.12±1.13	Anticancer activity depends on chirality. Both configurations (R) and (S) were active.	[86]
Cu‐61				11.91±1.17 10.97±1.22 16.24±1.41 16.21±1.41
Cu‐62	Square pyramidal and octahedral		MDA‐MB‐231 HUVEC	10.02±0.10 10.94±0.21	Anticancer activity depends on chirality and halogen substituents on the ligand.	[87]
Cu‐63	Octahedral			12.65±0.21 14.62±0.09